Latest Administration News

Anatara Lifesciences has successfully completed recruitment for the second stage of its pivotal GaRP-IBS clinical trial, with headline results expected in Q1 2025. The company also launched a new anti-obesity project and strengthened its cash position through recent capital raises.

Immuron has submitted its Phase 2 clinical study report for Travelan® to the FDA, revealing statistically significant immunological and microbiome benefits. The company is preparing to engage the FDA for Phase 3 trial discussions while progressing a large field study with military personnel.

ADX Energy has suspended testing at its Welchau-1 gas well in Upper Austria following a landmark Austrian Constitutional Court ruling that repealed a legal provision preventing environmental objections from halting operations. This development introduces regulatory uncertainty amid ongoing evaluation of the well’s potential.

Magnetic Resources NL reported a $4.39 million net cash outflow from operations in Q4 2024 but strengthened its balance sheet with a $9.41 million financing inflow, ending the quarter with $11.6 million in cash.

Basin Energy advances its Scandinavian uranium exploration with new land applications and awaits key sampling results, buoyed by Sweden's move to lift its uranium mining ban.

Telix Pharmaceuticals has exceeded its full-year 2024 revenue guidance, driven by strong sales of its prostate cancer diagnostic Illuccix® and strategic pipeline advancements.

Cassius Mining Limited has successfully raised $1 million through a share placement to fund its Soalara project in Madagascar and ongoing litigation in Ghana, signaling a strategic push in key operational areas.

True North Copper Limited (ASX: TNC) has been reinstated to trading following the appointment of voluntary administrators, signaling a critical juncture for the copper miner’s future.

True North Copper has successfully completed a $53.44 million capital raising and debt restructuring, exiting voluntary administration and securing ASX reinstatement. The company shifts focus to exploration at Mt Oxide and Cloncurry, retracting prior production plans for the next 12 months.

Pacific Edge faces a significant Medicare reimbursement setback as Novitas finalizes a non-coverage decision for its Cxbladder tests, prompting the company to activate legal challenges and operational restructuring.

EBR Systems has announced a rescheduling of the FDA Pre-Approval Inspection for its wireless cardiac pacing device to January 14, 2025, while maintaining its regulatory approval timeline for Q1 2025 and a commercial launch later in the year.

EBR Systems Inc. has responded to ASX's price query, denying any undisclosed information behind recent trading spikes and confirming compliance with listing rules. The company also flagged an upcoming FDA inspection announcement.